Mankind Pharma Ltd.

As of June 30, 2026, Mankind Pharma Ltd. carries a market capitalization of 1.05T, placing it among publicly traded companies globally. Its enterprise value stands at 1.05T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Mankind Pharma Ltd.'s next confirmed earnings release is scheduled for October 26, 2026.

As of June 30, 2026, Mankind Pharma Ltd. has 413.00M shares outstanding.

As of June 30, 2026, Mankind Pharma Ltd. trades at a trailing price-to-earnings ratio of 53.35.

As of June 30, 2026, Mankind Pharma Ltd. trades at an EV/EBITDA multiple of 29.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.20 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 38.48 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.05T versus a market cap of 1.05T, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 6.05M in revenue per employee across its workforce of 24,162.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Mankind Pharma Ltd. recorded 4.86B in income tax expense. That works out to an effective tax rate of 19.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 24.78B, leaving 19.69B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Mankind Pharma Ltd.'s stock has declined approximately 9.92% over the past 52 weeks. The 50-day moving average sits at 2,377.57, while the 200-day moving average is 2,307.07.

Over the twelve months ended June 30, 2026, Mankind Pharma Ltd. generated 146.11B in revenue and converted that into 19.69B in net income, yielding earnings per share of 48.19. EBITDA reached 36.23B, while operating income came in at 28.62B.

Over the twelve months ended June 30, 2026, Mankind Pharma Ltd. posted a gross margin of 72.02, reflecting its pricing power and cost economics. The operating margin of 19.59 and net profit margin of 13.48 provide insight into operational efficiency.